Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates

BACKGROUND: Patients with glucocorticoid-induced osteoporosis (GIOP) are at very high risk of fracture, and patients with severe GIOP often experience fractures during treatment with bisphosphonates. Teriparatide (TPTD) is the only currently available anabolic agent expected to be effective for GIOP...

Descripción completa

Detalles Bibliográficos
Autores principales: Seno, Takahiro, Yamamoto, Aihiro, Kukida, Yuji, Hirano, Aiko, Kida, Takashi, Nakabayashi, Amane, Fujioka, Kazuki, Nagahara, Hidetake, Fujii, Wataru, Murakami, Ken, Oda, Ryo, Fujiwara, Hiroyoshi, Kohno, Masataka, Kawahito, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940355/
https://www.ncbi.nlm.nih.gov/pubmed/27462504
http://dx.doi.org/10.1186/s40064-016-2704-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940355/
https://www.ncbi.nlm.nih.gov/pubmed/27462504
http://dx.doi.org/10.1186/s40064-016-2704-5

Ejemplares similares